Advertisement

Topics

EpimAb and Kymab enter into bispecific antibody cross-licensing deal

15:40 EDT 18 Oct 2016 | Elsevier Business Intelligence

EpimAb Biotherapeutics Inc. and Kymab Ltd. announced an immuno-oncology development and cross-licensing agreement for bispeci...

Original Article: EpimAb and Kymab enter into bispecific antibody cross-licensing deal

NEXT ARTICLE

More From BioPortfolio on "EpimAb and Kymab enter into bispecific antibody cross-licensing deal"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...